#United States #New York #Class Action #Securities Fraud #Cytokinetics

Class Action Filed Against Cytokinetics, Incorporated

On October 1, 2025, Levi & Korsinsky, LLP announced a class action lawsuit against Cytokinetics, Incorporated (NASDAQ: CYTK). This action aims to recover losses for investors adversely affected by alleged securities fraud occurring between December 27, 2023, and May 6, 2025. Investors are urged to take notice, as the deadline for joining this class action suit is swiftly approaching on November 17, 2025.

Understanding the Allegations

The lawsuit centers around claims that key figures within Cytokinetics made materially false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for their drug, aficamten. Initially, the defendants claimed that they anticipated FDA approval for the NDA in the latter half of 2025, counting on a Prescription Drug User Fee Act (PDUFA) date set for September 26, 2025. However, they failed to communicate significant risks surrounding the submission process for a Risk Evaluation and Mitigation Strategy (REMS), which was a necessary step to ultimately ensure regulatory approval.

In a striking turn of events, the truth emerged during an earnings call on May 6, 2025, where it was disclosed that Cytokinetics had engaged in various pre-NDA discussions with the FDA focusing on safety monitoring that necessitated a REMS submission. Despite this awareness, the decision was made to proceed with the NDA submission without including a REMS, depending solely on product labeling and voluntary education materials. This critical omission clearly indicated a disregard for known regulatory requirements and left investors misled about the timing associated with drug approval.

As a result of these actions, investors who purchased Cytokinetics common stock at inflated prices experienced significant financial losses when the reality of the situation came to light.

Call to Action for Affected Investors

If you are one of the investors who experienced losses during the specified timeframe, it is imperative that you act before the November 17, 2025, deadline to join the class action. Interested parties can seek to become appointed as lead plaintiffs in this case. It's important to note that participating in this suit doesn't require serving as a lead plaintiff; you may still be entitled to compensation regardless.

No costs or fees need to be incurred by class members participating in the lawsuit. Levi & Korsinsky, LLP emphasizes that their legal representation comes at no upfront cost to investors.

Why Levi & Korsinsky?

For over two decades, Levi & Korsinsky has established a robust reputation for safeguarding shareholder rights, securing hundreds of millions in compensation for aggrieved investors. Their dedicated team comprises over 70 legal professionals specializing in complex securities litigation, ensuring clients receive top-tier representation. Notably, the firm has consistently ranked in the ISS Securities Class Action Services' Top 50 Report for seven consecutive years, solidifying their status as one of the leading securities litigation firms in the nation.

How to Get Involved

Cytokinetics investors with inquiries or those who wish to join the class action can reach out for more information. Communications can be directed to:

• - Joseph E. Levi, Esq.
• - Email: [email protected]
• - Phone: (212) 363-7500

For more detailed information, investors may also utilize the link provided by Levi & Korsinsky: Cytokinetics Investor Lawsuit Submission Form.

In conclusion, those affected by the unfolding events at Cytokinetics should take advantage of this opportunity for legal recourse. With the deadline fast approaching, decisive action is encouraged to ensure participation in this class action lawsuit.